INNATE PHARMA (EPA:IPH) Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces its second participation to Actionaria, a forum dedicated to meeting with individual investors, on November 23 & 24, in Paris

Transparency directive : regulatory news

07/11/2012 07:15

Press release

                  INNATE PHARMA TO MEET ITS RETAIL INVESTORS
                      AT ACTIONARIA ON NOVEMBER 23 & 24

Marseilles, France, November 7, 2012

Innate Pharma SA (Euronext Paris: FR0010331421 - IPH), the innate immunity
company developing first-in-class drugs for cancer and inflammatory diseases,
announces its second participation to Actionaria, a forum dedicated to meeting
with individual investors, on November 23 & 24, in Paris.

"The potential for growth and innovation of companies within our sector is
attractive to retail investors. Innate continues to outperform the sector's
stockmarket performance, in large part because the market values our two
partnerships with major pharma leaders, the potential of our proprietary
pipeline as well as our financial security", commented Hervé Brailly, CEO of
Innate Pharma "Our retail shareholders base represents a significant part of
our capital and is a strength on which we intend to build for the long term
through events like Actionaria".

Innate Pharma representatives will be at booth A20, level 1 on 23 and 24
November. Hervé Brailly will participate in a number of conferences on Friday,
November 23:
  *  2:25 to 2:40pm : Presidents' Agora
  *  3:05 to 3:20pm: "Midcaps, the economic support of the regions?"
  *  3:30 to 4:30pm:  Conference-debate : "Midcaps: a socially responsible
                      investment"
  * 5:30 to 6:30pm:   Conference "Biotech, growth stocks to enhance your
                      portfolio"

To receive electronic invitations to Actionaria, please visit our website
(www.innate pharma.com). To receive paper invitations, please send an email to
investors@innate-pharma.com, stating your postal address and the desired
number of invitations.

Innate Pharma is committed to meet on a regular basis with the financial
community. Investors can also find updated information on the Company's
website and contact the investor relations team by writing to
investors@innate-pharma.com. They can also become member of the shareholders'
club (in French only) by following the link:
http://www.innatepharma.com/fr/finances/club-actionnaires.

About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. Its innovative approach has been validated by licence agreements with
two major pharmaceutical companies, Novo Nordisk A/S and Bristol-Myers Squibb.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate
Pharma is based in Marseilles, France, and had 81 employees as at
September 30, 2012.

Learn more about Innate Pharma at www.innate-pharma.com. Practical Information
about Innate Pharma shares:

ISIN code        FR0010331421
Ticker code      IPH

For additional information, please contact:
Innate Pharma                           ATCG Press
Laure-Hélène Mercier                    Marielle Bricman
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87             Mob.: +33 (0)6 26 94 18 53
investors@innate-pharma.com             mb@atcg-partners.com

121107 Actionaria

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces its second participation to Actionaria, a forum dedicated to meeting with individual investors, on November 23 & 24, in Paris

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories